Shionogi & Co., Ltd. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/16/2026)
| Balance Sheet | Total Assets | 2,576,870,000,000.00 | ROE | 65.40 % |
| Balance Sheet | Total Equity | 1,685,215,000,000.00 | ROA | 7.96 % |
| Cashflow | Capital Expenditures | -14,464,000,000.00 | P/FCF | 11.93 |
| Cashflow | Free Cash Flow | 199,108,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 213,572,000,000.00 | P/CF | 11.12 |
| Income | Earnings per Share (diluted) | 241.00 | Div. Yield | 2.37 % |
| Income | Net Income | 205,160,000,000.00 | P/E | 11.58 |
| Income | Shares Outstanding | 851,284,000.00 | P/B | 1.41 |
| Income | Total Revenue | 499,677,000,000.00 | P/S | 4.75 |
Ratios calculated on: 10/14/2026
Company Description
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company. It is engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides vitamin preparations, analgesic antipyretics, cold and sinus medicine, digestive medicine, dermatologic preparations, antiphlogistic analgetics, antihypercholesterolemic agents, test paper for glucose in urine and artificial teeth-related products. As of March 31, 2014, the Company had 37 subsidiaries and six associated companies.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.shionogi.co.jp
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more